The UK and US have reached a key bilateral deal that will preserve no levies on UK drug exports entering the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase spending on drugs through the NHS. This move ensures that duties on these vital exports will stay at zero for a timeframe of three years.
This deal is in response to previous threats to dramatically increase tariffs on patented drug imports, with figures floated as high as double the cost.
"This agreement between the United Kingdom reinforces the worldwide climate for innovative medicines and brings long-overdue balance to U.S.–U.K. medicine commerce," a release noted.
Trade Impact
Pharmaceuticals represent one of the UK's most significant exports to the United States, which is by far the primary buyer for major companies like GSK and AstraZeneca.
Trade data show that in the 12 months leading up to last September, the UK sold drugs worth billions to the US. This value represented 17.4% of all goods exports in that timeframe.
"This agreement protects work, stimulates funding and sets the stage for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Detailed UK Commitments
The deal entails several specific pledges from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a aim to increase total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to stay within budget will be capped at 15%. Previously, rebates were more than twenty percent.
Recent Tensions
This agreement follows a protracted row between the drug companies and the British authorities over drug pricing and regulatory access.
This friction were exacerbated by assertions that American customers were charged several times more for the equivalent treatments than consumers in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been delayed or abandoned, while major investments have been announced toward American operations.
One official publicly accepted that the NHS must increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a share of its total funding over the past decade.
